Literature DB >> 32439360

Preclinical study of influenza bivalent vaccine delivered with a two compartmental microneedle array.

Hye-Rin Jeong1, Joon-Yong Bae2, Jee-Hyun Park1, Seung-Ki Baek3, Gayeong Kim2, Man-Seong Park4, Jung-Hwan Park5.   

Abstract

Multiple vaccines can be mixed into a single combination to be a single product. However, combination vaccines have problems of complexity. In this study, microneedles were utilized in a compartmental microneedle array (CMA) to deliver two influenza vaccine strains without mixing. In this study, the CMA had two compartments, and two rectangular structures were attached to each end of the array to enable integration of the compartments with the coating equipment. The coating solution, which contained influenza vaccines for B/Yamagata (B-Y) and B/Victoria (B-V), was filled into the two reservoirs of the container. The CMA was aligned with the container for dipping the first compartment of the array into the first reservoir and the second compartment into the second reservoir. The CMA containing B-Y and B-V separately was administered to mice, and weight change and survival were compared with other groups of mice administered (a) combination vaccines with microneedles, (b) two monovalent vaccines with microneedles, (c) intramuscularly with a combination vaccine, and (d) intramuscularly with two monovalent vaccines. Plaque reduction neutralization tests were also performed to compare the CMA group with the other groups. The CMA showed a relative standard error of less than 7% between samples in dose uniformity. It also showed comparable antibody-forming efficacy compared to other groups, especially by B/Yamagata virus challenge. The CMA mice group showed better survival and weight change than mice that received intramuscular (IM) injection of the combination vaccine. In the neutralizing antibody experiment, all microneedle groups showed a higher neutralizing antibody than the IM groups. Vaccines were administered without mixing by a single administration using a CMA, and the CMA showed comparable efficacy with IM administration of the combination vaccine. Multivalent vaccines can be delivered without mixing as a single product by using a CMA.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B/Victoria; B/Yamagata; Bivalent influenza vaccine; Compartmental microneedle array; Influenza; Single administration

Mesh:

Substances:

Year:  2020        PMID: 32439360     DOI: 10.1016/j.jconrel.2020.05.024

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.

Authors:  Yura Shin; Jeonghun Kim; Jong Hyeon Seok; Heedo Park; Hye-Ran Cha; Si Hwan Ko; Jae Myun Lee; Man-Seong Park; Jung-Hwan Park
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 2.  Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.

Authors:  Jasmin Hassan; Charlotte Haigh; Tanvir Ahmed; Md Jasim Uddin; Diganta B Das
Journal:  Pharmaceutics       Date:  2022-05-16       Impact factor: 6.525

Review 3.  Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.

Authors:  Emrullah Korkmaz; Stephen C Balmert; Cara Donahue Carey; Geza Erdos; Louis D Falo
Journal:  Expert Opin Drug Deliv       Date:  2020-10-06       Impact factor: 8.129

Review 4.  Microarray patches enable the development of skin-targeted vaccines against COVID-19.

Authors:  Emrullah Korkmaz; Stephen C Balmert; Tina L Sumpter; Cara Donahue Carey; Geza Erdos; Louis D Falo
Journal:  Adv Drug Deliv Rev       Date:  2021-02-02       Impact factor: 17.873

Review 5.  Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.

Authors:  Ana Sara Cordeiro; Yogita Patil-Sen; Maitreyi Shivkumar; Ronak Patel; Abdulwahhab Khedr; Mohamed A Elsawy
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

6.  Elastic Bioresorbable Polymeric Capsules for Osmosis-Driven Delayed Burst Delivery of Vaccines.

Authors:  Kerr D G Samson; Eleonore C L Bolle; Mariah Sarwat; Tim R Dargaville; Ferry P W Melchels
Journal:  Pharmaceutics       Date:  2021-03-23       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.